News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug
09
FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing...
-
Aug
02
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Jul
07
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Jun
23
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food...
-
Jun
14
- Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is...
-
Jun
10
Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals HAMILTON, ON and...
-
Jun
09
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced updates on its...
-
Jun
08
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Jun
06
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
-
May
11
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
-
May
10
Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium supply chain...
-
May
04
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Apr
26
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
-
Mar
30
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Mar
24
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Mar
17
- Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZeneca - Recently signed research collaborations support expansion of pipeline into peptide-based...
-
Mar
09
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Feb
28
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
-
Feb
09
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Jan
21
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...
-
Jan
18
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...
-
Jan
11
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has...
-
Jan
11
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has...
-
Jan
10
Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc....
-
Nov
11
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company...